f98f9a57-095b-482a-893c-030f9ad9db02
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.420
- TNFA_SIGNALING_VIA_NFKB+0.420
- INTERFERON_ALPHA_RESPONSE+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- KRAS_SIGNALING_UP+0.280
- IL2_STAT5_SIGNALING+0.260
- INFLAMMATORY_RESPONSE+0.260
- COMPLEMENT+0.190
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.390
- OXIDATIVE_PHOSPHORYLATION-0.350
- DNA_REPAIR-0.310
- FATTY_ACID_METABOLISM-0.280
- MITOTIC_SPINDLE-0.250
- XENOBIOTIC_METABOLISM-0.240
- ESTROGEN_RESPONSE_LATE-0.230
- PROTEIN_SECRETION-0.230
- PEROXISOME-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-AAR3-01A-11R-A41B-07 | — | cohortA1 | 0.871 |
| 2 | MNG303 | — | — | 0.830 |
| 3 | SRR607445 | GTEX | — | 0.824 |
| 4 | TCGA-44-A47G-01A-21R-A24H-07 | — | cohortA1 | 0.814 |
| 5 | MNG943 | — | — | 0.813 |
| 6 | SRR934966 | — | — | 0.813 |
| 7 | SRR12475140 | — | — | 0.808 |
| 8 | TCGA-55-6987-01A-11R-1949-07 | — | cohortMD2 | 0.808 |
| 9 | SRR1335446 | GTEX | — | 0.807 |
| 10 | 3d89c16f-8045-4861-a82c-9f4624292284 | — | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |